Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

anti-Endoglin/CD105, Clone: E9, Novus Biologicals™

Mouse Monoclonal Antibody

Manufacturer:  Novus Biologicals NBP142383

Catalog No. NBP142383

This item has been discontinued by the manufacturer and is no longer available. Please call customer service for assistance: 1-800-766-7000.



Endoglin/CD105 Monoclonal antibody specifically detects Endoglin/CD105 in Human samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunoprecipitation, Immunohistochemistry-Frozen.


PBS containing 0.1% BSA with 0.02% Sodium Azide
The antibody reacts with the CD105 antigen.
Protein A or G purified
Store at 4C. Do not freeze.
The monoclonal antibody E9 reacts with Endoglin a 190 kDa homodimeric transmembrane glycoprotein composed of disulfide-linked subunits. The external domain binds TGF-beta1 and -beta3 isoforms with high affinity. Two different isoforms (L and S) of CD105 with capacity to bind TGF-beta have been characterized which differ in the amino acid composition of their cytoplasmic tails. Mutations in the gene encoding endoglin have been linked to the human disease hereditary hemorrhagic telangiectasia type 1 (HHT1) a vascular disorder characterized by localized vascular dysplasia and a tendency towards arteriovenous malformations. Mice expressing a single CD105 allele develop external signs of disease similar to human HHT1, supporting the haploinsufficiency model for HHT1. Mice lacking endoglin die from defective angiogenesis characterized by failure of vascular smooth muscle investment of embryonic blood vessels, suggesting a defect in vascular smooth muscle cell development. Microvessel density (MVD) has been reported to be an independent prognostic indicator of outcome in a variety of human malignancies, with increased MVD correlating with shorter overall and relapse-free survival rates. The MVD counts using anti-CD105 antibody significantly correlated with overall and disease-free survival. Anti-CD105 monoclonal antibody E9 and anti-CD34 monoclonal antibody have been successfully used to quantify MVD in human breast carcinoma
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunoprecipitation, Immunohistochemistry (Frozen)
0.1 mg/mL
Western Blot 1:100-1:2000, Flow Cytometry 1:10-1:1000, ELISA 1:100-1:2000, Immunohistochemistry 1:10-1:500, Immunoprecipitation 1:10-1:500, Immunohistochemistry-Frozen 1:10-1:500
CD105, CD105 antigen, endoglin, ENDOsler-Rendu-Weber syndrome 1, HHT1FLJ41744, ORW, ORW1
0.05 mg
Cancer, Cell Biology, Cellular Markers, Endothelial Cell Markers, Extracellular Matrix, Hypoxia, Immunology, Mesenchymal Stem Cell Markers, Stem Cell Markers
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

For Research Use Only